Journal of Clinical Endocrinology and Metabolism (journal-of-clinical-endocrinology-and-metabolism)

Journal positioning

The Journal of Clinical Endocrinology and Metabolism (JCEM, Endocrine Society / Oxford University Press) is the Endocrine Society's flagship clinical journal, publishing research across the full breadth of clinical endocrinology and metabolism — thyroid, adrenal, pituitary/neuroendocrine, bone and mineral, reproductive endocrinology, obesity, lipid, and diabetes/metabolism — with an emphasis on human, patient-oriented studies that inform endocrine diagnosis and management. Its defining expectation is a clinically important advance in the diagnosis, treatment, or pathophysiology of an endocrine or metabolic disorder in humans, not a narrow single-center series, a pure animal study with no human translation, or a diabetes-only paper better placed in a dedicated diabetes journal. Breadth across endocrine organs is a feature: JCEM is the generalist endocrine venue. This skill is a fit / venue-selection / re-framing aid; it is not clinical or regulatory advice and does not replace the journal's current instructions for authors. Before submitting, re-check the live JCEM author instructions.

When to trigger

• The author names JCEM for a clinical-endocrinology or metabolism study across any

endocrine organ system and wants a fit/framing check.

• An endocrine study must be re-framed around a patient-oriented diagnostic, therapeutic,

or pathophysiologic question.

• The author is choosing between JCEM (broad endocrine), Diabetologia (diabetes-specific),

and The Lancet Diabetes & Endocrinology (high-impact trials).

• The author needs the journal's reporting-guideline, registration, and human-endocrine-study

expectations.

Scope & topic fit

• Thyroid, adrenal, and pituitary/neuroendocrine disorders: diagnosis, hormone assays,

and management studies.

• Bone, mineral, and calcium metabolism: osteoporosis, parathyroid, and vitamin-D

endocrinology.

• Reproductive and developmental endocrinology: PCOS, hypogonadism, fertility, and

pubertal/growth disorders.

• Obesity, lipid, and energy metabolism with endocrine mechanism or clinical management

endpoints.

• Diabetes and glucose metabolism as part of broad endocrine practice (with awareness of

diabetes-dedicated venues).

• Endocrine clinical trials, cohorts, biomarker/hormone-assay validation, and

pharmacologic/hormone-therapy studies in humans.

Method & evidence bar

• Studies must be adequately powered with prespecified, patient-centered endocrine

endpoints; surrogate hormone endpoints need clinical justification.

• The applicable reporting guideline and checklist are expected: CONSORT for trials,

STROBE for observational work, PRISMA for systematic reviews, STARD for diagnostic/assay accuracy.

• Trials require prospective registration and the registration number; protocol/SAP are

expected.

• Hormone assays and biomarker methods must be validated and described (platform,

reference intervals, harmonization); analytic rigor is scrutinized.

• Observational claims must address confounding, bias, and missing data; causal language

must match the design.

• Effect estimates need confidence intervals and absolute as well as relative measures;

clinical significance must be argued.

Structure & house style

• Endocrine Society/OUP format with a structured abstract and a precis/context-and-significance

statement; re-check current article types (Clinical Research Article, etc.) and limits on the live guide.

• The introduction frames the endocrine clinical question; the discussion states the

diagnostic or management implication plainly.

• A CONSORT/STROBE/PRISMA/STARD flow diagram is expected for the relevant design.
• Tables/figures follow the journal's statistical-reporting standards; a supplement carries

the protocol, full assay/statistical methods, and additional analyses.

Official-submission checklist

• Before giving submission-ready advice, read ../../resources/source-basis.md and

../../resources/official-source-map.md; start from the ICMJE/EQUATOR and Endocrine Society/OUP anchors, then cite the current JCEM page you checked.

• Search the live site for "JCEM Endocrine Society instructions for authors" and follow

the current version.

• Re-check article types, abstract and precis format, and word/figure/reference limits.
• Confirm trial registration, the reporting checklist (CONSORT/STROBE/PRISMA/STARD),

assay-validation reporting, data/code-availability, and protocol/SAP submission.

• Re-check IRB/ethics and consent, ICMJE authorship and conflict-of-interest disclosure,

funding, and AI-use disclosure.

• If the live official instructions conflict with this skill, the official instructions

win.

Pre-submission self-check

• [ ] The study answers a patient-oriented endocrine diagnostic, therapeutic, or pathophysiologic question.
• [ ] Endocrine endpoints are prespecified and powered; trials are registered with the number in the manuscript.
• [ ] The correct reporting checklist (CONSORT/STROBE/PRISMA/STARD) is completed and attached.
• [ ] Hormone assays/biomarkers are validated and fully described.
• [ ] Confounding, bias, and missing data are addressed; causal language matches the design.
• [ ] IRB/consent, ICMJE disclosures, and a data-availability statement are prepared.

Common desk-reject triggers

• Single-center descriptive series with limited generalizability and no clear management change.
• Pure animal/cell endocrine studies with no human translation or clinical relevance.
• Unvalidated or poorly described hormone assays underpinning the main claim.
• Missing trial registration, protocol, or the required reporting checklist.
• Diabetes-only or single-trial work better placed in a dedicated diabetes or high-impact venue.

Re-routing decision

• Diabetes-focused clinical/epidemiologic or basic study → diabetologia.
• High-impact diabetes/endocrine trial with broad reach → the-lancet-diabetes-and-endocrinology.
• Diabetic kidney disease centered on nephrology → journal-of-the-american-society-of-nephrology / kidney-international.
• Endocrine surgery (thyroid/adrenal/pituitary surgical outcomes) → jama-surgery.
• Broad practice-changing endocrine trial → general medicine (jama / NEJM / The Lancet in the natural-science bundle).

Output format

[Fit] High / Medium / Low (one-line reason)
[Target] Journal of Clinical Endocrinology and Metabolism (Endocrine Society/OUP)
[Specialty tags] <thyroid / adrenal / pituitary / bone-mineral / reproductive / metabolism>
[Study design / reporting guideline] <RCT-CONSORT / cohort-STROBE / review-PRISMA / assay-STARD>
[Method/evidence] <power, assay validation, design, registration>
[Top risk] <the single most likely reason for rejection>
[Official items to re-check] <article type / registration / checklist / assay reporting / ethics / disclosures>
[Re-route suggestion] <if not a fit, a better-matched venue>